The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells.
Open accessAbstract
CTLA-4 is a T cell antigen that is structurally related to CD28 and serves as a high affinity ligand for the B cell antigen B7-1/2. Unlike CD28, the function of CTLA-4 is unclear, although reports have implicated the antigen in the costimulation of T cells. Recently, phosphatidylinositol 3-kinase (PI 3-kinase) has been implicated in the costimulatory function of CD28 by virtue of its ability to bind to a pYMNM motif within the cytoplasmic tail of the antigen. In this study, we show that CTLA-4 can also associate with PI 3-kinase as detected by lipid kinase analysis and immunoblotting with anti-p85 antiserum. High pressure liquid chromatographic separation of deacylated lipids showed the presence of a peak corresponding to PI-3-P. Anti-CTLA-4 ligation of the receptor induced a significant increase in the levels of precipitable PI 3-kinase activity. Peptide binding studies revealed that the NH2- and COOH-terminal SH2 domains of p85 bind the CTLA-4 cytoplasmic pYVKM motif with an affinity (ID50: 0.6 and 0.04 microM), that is similar to CD28. CTLA-4 binding to PI 3-kinase provides further evidence that CTLA-4 is not an inert counterreceptor, but rather is coupled to an intracellular signaling molecule with the capacity to regulate cell growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050 · cited 1×
“T cell nonresponsiveness or anergy can be reversed by CD28 engagement, an event of potential importance in the generation of cytolytic responses against tumors (10, 11).”
Background
Cited by
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
T-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Self-citationCTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2541 · Cited by 801
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518
Adaptors for Clathrin-Mediated Traffic
Kirchhausen, T. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.705 · Cited by 427
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392
Self-citationBour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Shiratori, T., Miyatake, S., Ohno, H., Nakaseko, C., Isono, K., Bonifacino, J. S., & Saito, T. (1997) · Immunity · doi:10.1016/s1074-7613(00)80346-5 · Cited by 345
The CD28 and CTLA-4 Receptors Associate with the Serine/Threonine Phosphatase PP2A
Chuang, E., Fisher, T. S., Morgan, R. W., Robbins, M. D., Duerr, J. M., Vander Heiden, M. G., Gardner, J. P., Hambor, J. E., Neveu, M. J., & Thompson, C. B. (2000) · Immunity · doi:10.1016/s1074-7613(00)00031-5 · Cited by 303
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 297
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Structural Analysis of CTLA-4 Function In Vivo
Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L., & Thompson, C. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5319 · Cited by 252
Leung, H. T., Bradshaw, J., Cleaveland, J. S., & Linsley, P. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.25107 · Cited by 191
CTLA-4 trafficking and surface expression
Valk, E., Rudd, C. E., & Schneider, H. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.011 · Cited by 177
Self-citationCD28: a signalling perspective
WARD, S. G. (1996) · Biochemical Journal · doi:10.1042/bj3180361 · Cited by 149
Regulation of Cytotoxic T Lymphocyte-Associated Molecule-4 by Src Kinases
Chuang, E., Lee, K.-M., Robbins, M. D., Duerr, J. M., Alegre, M.-L., Hambor, J. E., Neveu, M. J., Bluestone, J. A., & Thompson, C. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1270 · Cited by 119
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA
Gavrieli, M., & Murphy, K. M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.036 · Cited by 85
CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts
Olsson, C., Riebeck, K., Dohlsten, M., & Michaëlsson, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14400 · Cited by 84
Valk, E., Leung, R., Kang, H., Kaneko, K., Rudd, C. E., & Schneider, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.024 · Cited by 78
Self-citationTyrosine Phosphatase SHP-2 Binding to CTLA-4: Absence of Direct YVKM/YFIP Motif Recognition
Schneider, H., & Rudd, C. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2234 · Cited by 78
Self-citationSrc Family Tyrosine Kinases Associate with and Phosphorylate CTLA-4 (CD152)
Miyatake, S., Nakaseko, C., Umemori, H., Yamamoto, T., & Saito, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9191 · Cited by 65
Metadata
- Authors
- Schneider, H., Prasad, K. V., Shoelson, S. E., & Rudd, C. E.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-01-01
- Volume
- 181
- Issue
- 1
- Pages
- 351-355
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2104036678
- Cited by
- 165
- References
- 3
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.